Larvol Delta - BioAge-Announces-Indication-Expansion-for-Oral-NLRP3-Inhibitor-BGE102-with-Plans-to-Initiate-Phase-1b2a-ProofofConcept-Clinical-Trial-in-Patients-with-Diabetic-Macular-Edema-in-Mid2026

BGE-102 - BioAge Labs

https://www.globenewswire.com/news-release/2026/01/20/3221761/0/en/BioAge-Announces-Indication-Expansion-for-Oral-NLRP3-Inhibitor-BGE-102-with-Plans-to-Initiate-Phase-1b-2a-Proof-of-Concept-Clinical-Trial-in-Patients-with-Diabetic-Macular-Edema-in.html

Jan 20, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next